Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
ConclusionsSodium-glucose cotransporter inhibitors significantly reduced major adverse cardiovascular events, including hospitalization and all-cause mortality in patients with or without established atherosclerotic cardiovascular disease. We observed a beneficial trend in patients with heart failure with preserved ejection fraction, and no benefi ts in patients with stroke or myocardial infarction.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Heart Failure | Hypertension | Smokers | Sodium | Stroke | Study